UK Gov
Change to the information provided on adverse events in the Summary of Product Characteristics (SPC).
Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPC) in Great Britain for the following have been updated.
- Librela 5mg Solution for Injection for Dogs
- Librela 10mg Solution for Injection for Dogs
- Librela 15mg Solution for Injection for Dogs
- Librela 20mg Solution for Injection for Dogs
- Librela 30mg Solution for Injection for Dogs
Section 4.6 now additionally states that in very rare cases, joint swelling, joint pain, bone and joint disorder and soft tissue ossification have been reported.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
